Boceprevir

Catalog No.S3733 Synonyms: EBP 520, SCH 503034

For research use only.

Boceprevir (EBP 520, SCH 503034) is an oral, direct acting hepatitis C virus (HCV) protease inhibitor with Ki value of 14 nM for NS3. It is used in combination with other antiviral agents in the treatment of chronic hepatitis C, genotype 1.

Boceprevir Chemical Structure

CAS No. 394730-60-0

Selleck's Boceprevir has been cited by 9 Publications

Purity & Quality Control

Choose Selective HCV Protease Inhibitors

Other HCV Protease Products

Biological Activity

Description Boceprevir (EBP 520, SCH 503034) is an oral, direct acting hepatitis C virus (HCV) protease inhibitor with Ki value of 14 nM for NS3. It is used in combination with other antiviral agents in the treatment of chronic hepatitis C, genotype 1.
Targets
NS3/4A protease [1]
14 nM(Ki)
In vitro

Treatment with NLRP3 Inflammasome Inhibitor I significantly limits IL-1β release after LPS and ATP challenge. NLRP3 Inflammasome Inhibitor I is not a caspase-1 inhibitor[1].

In vivo The small molecule NLRP3 Inflammasome Inhibitor I, an intermediate substrate in the glyburide synthesis free of the cyclohexylurea moiety, inhibits the formation of the NLRP3 inflammasome in cardiomyocytes and limits the infarct size following myocardial ischemia/reperfusion in the mouse, without affecting glucose metabolism[1].

Protocol (from reference)

Cell Research:[1]
  • Cell lines: J774A.1 cells
  • Concentrations: 400 μM
  • Incubation Time: 30 mins
  • Method: J774A.1 cells, a murine macrophage cell line, are plated at 5×104 cells/well in a 96 multiwell plate for 24 hours in RPMI medium supplemented with 10% of fetal bovine serum (FBS). The cells are primed with Escherichia coli 0111:B4 LPS(1 μg/ml) for 4 hours and then ATP (5 mM) for 30 minutes to induce the NLRP3 inflammasome formation. The supernatants are collected and levels of IL-1β are measured with a mouse IL-1β ELISA kit. To test the inhibitory effects of 16673-34-0 on NLRP3 inflammasome activation, cells are co-treated with 16673-34-0 (400μM) or Glyburide (400μM) at the time of ATP for 30 minutes, and IL-1β levels are used as read-out.
Animal Research:[1]
  • Animal Models: CD1 mice
  • Dosages: 100 mg/kg
  • Administration: i.p.

Solubility (25°C)

In vitro

Chemical Information

Molecular Weight 519.68
Formula

C27H45N5O5

CAS No. 394730-60-0
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles CC1(C2C1C(N(C2)C(=O)C(C(C)(C)C)NC(=O)NC(C)(C)C)C(=O)NC(CC3CCC3)C(=O)C(=O)N)C

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT01909401 Completed Drug: boceprevir Liver Transplantation Indiana University|Merck Sharp & Dohme LLC June 2013 Early Phase 1
NCT01821625 Terminated Drug: Eltrombopag Thrombocytopenia|Hepatitis C University of Texas Southwestern Medical Center|GlaxoSmithKline April 2013 Phase 2|Phase 3
NCT01499498 Completed Drug: Sildenafil and Boceprevir Hepatitis C Imperial College London December 2012 Phase 1
NCT01663922 Completed Drug: Boceprevir|Drug: St John''s Wort Hepatitis C St Stephens Aids Trust|University of Liverpool|University of Turin Italy August 2012 Phase 1
NCT01657552 Completed Drug: Eltrombopag|Drug: Boceprevir|Drug: Telaprevir Thrombocytopaenia GlaxoSmithKline August 1 2012 Phase 1

(data from https://clinicaltrials.gov, updated on 2022-08-01)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Boceprevir | Boceprevir supplier | purchase Boceprevir | Boceprevir cost | Boceprevir manufacturer | order Boceprevir | Boceprevir distributor